Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases.

Aki MorikawaElisa de StanchinaElena PentsovaMargaret M KemenyBob T LiKendrick TangSujata PatilMartin FleisherCatherine Van PoznakLarry NortonAndrew D Seidman

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

High-dose lapatinib is tolerable when given intermittently and sequentially with capecitabine. Antitumor activity was noted in both CNS and non-CNS sites of disease. This novel administration regimen is feasible and efficacious in patients with HER2+ breast cancer with CNS metastasis and warrants further investigation.

Keyphrases

positive breast cancer
high dose
metastatic breast cancer
blood brain barrier
low dose
stem cell transplantation
phase ii study
locally advanced
metastatic colorectal cancer
phase iii
cerebrospinal fluid
childhood cancer